Building a synthetic biology-rich biotech business from scratch

The SYNBIOCHEM-SynbiCITE 4-day MBA course is designed to provide the skills required to establish, build and manage a biotech company.

 

SYNBIOCHEM and SynbiCITE are inviting future biotechnology leaders to invest in their 4-Day More Business Acumen (MBA) programme and start their entrepreneurial journey in synthetic biology for industrial biotechnology.

SYNBIOCHEM is a UK/European Centre of Excellence for the synthetic biology of fine and speciality chemicals production (including new products and intermediates for drug development, agrochemical and new materials for sustainable bio-manufacturing). SynbiCITE is the Innovation and Knowledge Centre (IKC) for Synthetic Biology, based at Imperial College London.

The course is aimed at budding entrepreneurs, from postgraduates to seasoned academics who want to gain a thorough understanding and start a business in the biotechnology sector.

The course draws upon the experiences of seasoned entrepreneurs, patent attorneys and investors and has a particular focus on set-up, funding and intellectual property (IP). During the course, participants will develop real biotech business ideas and pitch them to venture capitalists.

Photo galleries are not available for content from the previous KTN website: we apologise for this.

 

The next edition of this 4-day MBA will take place on 19-23 November 2017 at the Manchester Institute of Biotechnology at the University of Manchester.

Places are limited (30) and applicants will be selected on the basis of their application and demonstration of their potential to take their inspiration to innovation and beyond.

Please click here to find out more about the MBA (the last date for applications is 6th November).

 

You may also be interested in the Engineering Biology session at KTN’s Chemistry and Industrial Biotechnology Showcase (20-21 September, York) which will highlight some of the thriving start-ups at the leading edge of chemical applications of engineering biology, and how larger corporations are adopting such technologies.

If you would like to discuss opportunities and support mechanisms for innovation in synthetic biology please contact Amy Tayler (Knowledge Transfer Manager, Synthetic Biology).